192 related articles for article (PubMed ID: 37211170)
21. Early glycolytic reprogramming controls microglial inflammatory activation.
Cheng J; Zhang R; Xu Z; Ke Y; Sun R; Yang H; Zhang X; Zhen X; Zheng LT
J Neuroinflammation; 2021 Jun; 18(1):129. PubMed ID: 34107997
[TBL] [Abstract][Full Text] [Related]
22. Glycometabolic Reprogramming of Microglia in Neurodegenerative Diseases: Insights from Neuroinflammation.
Huang Q; Wang Y; Chen S; Liang F
Aging Dis; 2024 May; 15(3):1155-1175. PubMed ID: 37611905
[TBL] [Abstract][Full Text] [Related]
23. Calpain activation and progression of inflammatory cycles in Parkinson's disease.
Gao A; McCoy HM; Zaman V; Shields DC; Banik NL; Haque A
Front Biosci (Landmark Ed); 2022 Jan; 27(1):20. PubMed ID: 35090325
[TBL] [Abstract][Full Text] [Related]
24. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
[TBL] [Abstract][Full Text] [Related]
25. Neuroinflammatory Responses and Parkinson' Disease: Pathogenic Mechanisms and Therapeutic Targets.
Yang L; Mao K; Yu H; Chen J
J Neuroimmune Pharmacol; 2020 Dec; 15(4):830-837. PubMed ID: 32529463
[TBL] [Abstract][Full Text] [Related]
26. What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson's Disease?
Xue J; Tao K; Wang W; Wang X
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338925
[TBL] [Abstract][Full Text] [Related]
27. Identification of Clec7a as the therapeutic target of rTMS in alleviating Parkinson's disease: targeting neuroinflammation.
Chen XY; Feng SN; Bao Y; Zhou YX; Ba F
Biochim Biophys Acta Mol Basis Dis; 2023 Dec; 1869(8):166814. PubMed ID: 37495085
[TBL] [Abstract][Full Text] [Related]
28. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
[TBL] [Abstract][Full Text] [Related]
29. TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease.
Zhang Y; Feng S; Nie K; Li Y; Gao Y; Gan R; Wang L; Li B; Sun X; Wang L; Zhang Y
Biochem Biophys Res Commun; 2018 May; 499(4):797-802. PubMed ID: 29621548
[TBL] [Abstract][Full Text] [Related]
30. Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease.
Panicker N; Saminathan H; Jin H; Neal M; Harischandra DS; Gordon R; Kanthasamy K; Lawana V; Sarkar S; Luo J; Anantharam V; Kanthasamy AG; Kanthasamy A
J Neurosci; 2015 Jul; 35(27):10058-77. PubMed ID: 26157004
[TBL] [Abstract][Full Text] [Related]
31. Menstrual blood-derived endometrial stem cells alleviate neuroinflammation by modulating M1/M2 polarization in cell and rat Parkinson's disease models.
Li H; Wei J; Zhang Z; Li J; Ma Y; Zhang P; Lin J
Stem Cell Res Ther; 2023 Apr; 14(1):85. PubMed ID: 37055866
[TBL] [Abstract][Full Text] [Related]
32. Microglial Metabolic Reprogramming: Emerging Insights and Therapeutic Strategies in Neurodegenerative Diseases.
Miao J; Chen L; Pan X; Li L; Zhao B; Lan J
Cell Mol Neurobiol; 2023 Oct; 43(7):3191-3210. PubMed ID: 37341833
[TBL] [Abstract][Full Text] [Related]
33. Programmed Death-1 Deficiency Aggravates Motor Dysfunction in MPTP Model of Parkinson's Disease by Inducing Microglial Activation and Neuroinflammation in Mice.
Cheng YY; Chen BY; Bian GL; Ding YX; Chen LW
Mol Neurobiol; 2022 Apr; 59(4):2642-2655. PubMed ID: 35142987
[TBL] [Abstract][Full Text] [Related]
34. Modulation of Inflammatory Mediators and Microglial Activation Through Physical Exercise in Alzheimer's and Parkinson's Diseases.
de Almeida EJR; Ibrahim HJ; Chitolina Schetinger MR; de Andrade CM; Cardoso AM
Neurochem Res; 2022 Nov; 47(11):3221-3240. PubMed ID: 35962936
[TBL] [Abstract][Full Text] [Related]
35. A novel synthetic peptide SVHRSP attenuates dopaminergic neurodegeneration by inhibiting NADPH oxidase-mediated neuroinflammation in experimental models of Parkinson's disease.
Zhang X; Tu D; Li S; Li N; Li D; Gao Y; Tian L; Liu J; Zhang X; Hong JS; Hou L; Zhao J; Wang Q
Free Radic Biol Med; 2022 Aug; 188():363-374. PubMed ID: 35760232
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease.
Gorelenkova Miller O; Behring JB; Siedlak SL; Jiang S; Matsui R; Bachschmid MM; Zhu X; Mieyal JJ
Antioxid Redox Signal; 2016 Dec; 25(18):967-982. PubMed ID: 27224303
[TBL] [Abstract][Full Text] [Related]
37. Anti-Inflammatory and Neuroprotective Mechanisms of GTS-21, an α7 Nicotinic Acetylcholine Receptor Agonist, in Neuroinflammation and Parkinson's Disease Mouse Models.
Park JE; Leem YH; Park JS; Kim DY; Kang JL; Kim HS
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457238
[TBL] [Abstract][Full Text] [Related]
38. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
[TBL] [Abstract][Full Text] [Related]
39. Active ingredients of Chinese medicine with immunomodulatory properties: NF-κB pathway and Parkinson's disease.
Song J; Zhao Y; Shan X; Luo Y; Hao N; Zhao L
Brain Res; 2024 Jan; 1822():148603. PubMed ID: 37748570
[TBL] [Abstract][Full Text] [Related]
40. Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice.
Szego EM; Malz L; Bernhardt N; Rösen-Wolff A; Falkenburger BH; Luksch H
Elife; 2022 Oct; 11():. PubMed ID: 36314770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
